Project Grant HT9425261E049
- Federal Project Grant Award Summary Cincinnati Children's Hospital Medical Center received a $249,999 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 15, 2025, with completion by September 14, 2027. The project, titled "Assessment of Smoldering Glial Activation in Pediatric-Onset MS by Novel Neuroimaging," focuses on advanced neuroimaging research to evaluate glial activation...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $321,000 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective November 1, 2025 through October 31, 2027. The research project, titled "MicroRNA-Induced Silencing as Treatment Target in Autism-Associated Deficits in Cortical Morphology and Behavior," investigates microRNA (miRNA) mechanisms as a potential...
- Federal Grant Award Summary The Cleveland Clinic Foundation received a $750,000 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period of April 1, 2026 through March 31, 2029. The award supports research investigating focal adhesion dependencies in CDH1-deficient lobular breast cancers, with performance occurring at the Cleveland Clinic Health System facility in Cleveland, Ohio. This research initiative aligns...
- Federal Grant Award Summary The University of Cincinnati's Sponsored Research Services Division received $817,828 in Project Grant funding from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period of August 1, 2025, through July 31, 2028. The award supports research investigating nuclear translocation of mutant nuclear envelope proteins and their role in conferring G-CSF (granulocyte colony-stimulating factor) resistance in...
- Federal Grant Award Summary The Defense Health Agency awarded a $1.65M Project Grant to the University of California, San Diego (UCSD) under the Military Medical Research and Development program (CFDA 12.420) for research targeting oncoembryonic antigens to overcome therapy resistance in patients with triple-negative breast cancer. The award, effective May 1, 2026, through April 30, 2029, supports advanced biomedical research aimed at developing novel therapeutic approaches to address a critical...
- Federal Grant Award Summary Baylor College of Medicine received a $720,000 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025 through August 31, 2028. The grant funds research focused on targeting cryptic splicing-derived neoantigens in HNRNPM-dysregulated triple-negative breast cancer. This research initiative represents the DHA's commitment to advancing biomedical solutions relevant to...
- Federal Grant Award Summary The Children's Hospital of Philadelphia Research Institute received a $934,501 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025 through August 31, 2028. The award supports research focused on developing peptide-centric chimeric antigen receptor (CAR) T-cell therapies for neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors...
- Federal Project Grant Award Summary Baylor College of Medicine was awarded $480,000 by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on September 1, 2025, for a three-year project through August 31, 2028. The research project, titled "Targeting Cryptic Splicing-Derived Neoantigens in HNRNPM-Dysregulated Triple-Negative Breast Cancer," focuses on identifying and developing immunotherapeutic approaches against novel cancer...
- Federal Grant Award Summary The Research Institute at Nationwide Children's Hospital received a $307,892 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on April 15, 2025, with completion scheduled for April 14, 2028. This three-year research initiative focuses on developing novel probiotic ride-share technology designed to improve brain-gut microbiome interactions. The award supports hypothesis-driven...
- This $1,354,428 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will fund a family-centered e-health intervention to promote patient and caregiver well-being in adolescent and emerging adult pediatric brain tumor survivors. The grant was awarded to the Children's Hospital Medical Center in Cincinnati, Ohio, which will serve as the prime awardee. The project duration is from September 1, 2024 to August 31, 2028. The...
Cincinnati Children's Hospital Medical Center received a $750,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to support research targeting epigenetic mechanisms that drive triple-negative breast cancer. The award, effective April 1, 2026 through March 31, 2029, will be conducted at the hospital's Cincinnati, Ohio facility. This three-year initiative aligns with the Defense Health Agency's mission to advance biomedical research that transforms healthcare for military service members and the American public through innovative and impactful scientific investigation. The research project focuses on elucidating the epigenetic drivers underlying triple-negative breast cancer, a particularly aggressive form of breast cancer with limited treatment options. Cincinnati Children's Hospital Medical Center, as a leading pediatric research institution with extensive federal grant portfolio and established expertise in cancer biology and translational research, will conduct the hypothesis-driven research necessary to develop novel diagnostic tools and therapeutic interventions. The funding supports the hospital's research infrastructure and personnel dedicated to this critical cancer research initiative.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $750.0k | 3/19/26 |